Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Cardiology

Getting the Right Diagnosis: Testing and Look-Alikes

At a Glance

Hypertensive heart disease is diagnosed by combining a history of high blood pressure with heart tests—especially an echocardiogram and sometimes cardiac MRI—while checking for other causes of heart thickening, including an inherited condition or intense athletic training.

Confirming a diagnosis of hypertensive heart disease (HHD) is a process of connecting the dots between your blood pressure history and the physical state of your heart. Because the heart can thicken for many reasons—ranging from intense athletic training to rare genetic conditions—doctors use a specific set of tests to ensure they are treating the right underlying cause [1][2].

The Diagnostic Toolset

Your care team uses several layers of testing to see how your heart has adapted to high pressure. HHD is a clinical diagnosis, and tests help build the picture.

  • Electrocardiogram (ECG/EKG): This is a basic test of your heart’s electrical activity. While it is not as sensitive as imaging, it can show “voltage criteria” (stronger electrical signals) that suggest the heart muscle has become thicker [3][4].
  • Echocardiogram (Echo): This ultrasound is the preferred first-line structural test for the initial diagnosis. It measures the thickness of the heart walls and the size of the chambers to calculate your Left Ventricular Mass Index (LVMI)—the weight of your heart muscle relative to your body size [5][1].
  • Cardiac MRI (CMR): If your Echo results are unclear, an MRI provides a high-definition look at the heart tissue. It can estimate diffuse tissue changes through techniques like T1 mapping and Extracellular Volume (ECV) measurement, which detect changes that an ultrasound cannot see. Note that these estimate tissue changes and do not directly prove permanent microscopic scarring [6][7].
  • Laboratory Tests: High blood pressure often affects the kidneys as well. Tests like the urine albumin-creatinine ratio (UACR) check for protein leaks, which can signal that the high pressure is causing widespread “organ damage.” However, diabetes or primary kidney disease must also be considered [2][8].

Ruling Out ‘Look-Alike’ Conditions

Not all thick hearts are caused by blood pressure. Your doctor must distinguish HHD from other conditions that require very different treatments [9]:

  • Hypertrophic Cardiomyopathy (HCM): This is a genetic condition where the heart muscle thickens abnormally. While HHD usually thickens the heart evenly (concentric hypertrophy), HCM often thickens one part more than others, such as the septum between the chambers, though it can have concentric patterns too [10][11].
  • Athlete’s Heart: Intense, long-term exercise can cause the heart to enlarge naturally. While an athlete’s heart typically has normal relaxation, minor abnormal findings can occur, requiring specialist interpretation [12][13].
  • Secondary Hypertension: Sometimes, high blood pressure is caused by a different medical issue, such as a narrowing of the kidney arteries or a hormone condition (like primary aldosteronism in Conn’s Syndrome). If your blood pressure is very hard to control, your doctor may look for these “secondary” causes [14][15]. Infiltrative cardiomyopathies and chronic kidney disease are also differentials.

Your Diagnostic Completeness Checklist

When you review your medical reports (Echo or MRI), look for these key measurements. If they are missing, do not assume the test is incomplete—not every measurement is needed for every patient. A missing metric does not mean a report is invalid:

Measurement What It Tells You
LV Mass Index (LVMI) The actual “weight” of your heart muscle; it defines the severity of the thickening [5]. Normal ranges depend on sex and body size.
Relative Wall Thickness (RWT) Used with LV mass to classify geometry [3].
Ejection Fraction (EF) The percentage of blood pumped out with each beat; often normal in early HHD [16].
Diastolic Function (E/e’ ratio) An imperfect estimate of filling pressure [17].
Left Atrial Volume Index (LAVI) The size of the heart’s upper chamber; an enlarged atrium is a nonspecific sign of long-term pressure stress [18].
Global Longitudinal Strain (GLS) A sensitive measure of how well the heart fibers are contracting, which can show damage even if the EF is normal. Not required for routine HHD diagnosis [19].
T1 / ECV (MRI only) Context-dependent markers of diffuse tissue changes within the heart muscle [6].

Identifying these specific markers helps your care team move beyond a simple “high blood pressure” diagnosis to a personalized plan for protecting your heart muscle [20].

Common questions in this guide

What test is usually used first to check for hypertensive heart disease?
An echocardiogram is usually the preferred first-line imaging test because it measures heart-wall thickness, chamber size, and left ventricular mass. An ECG may show electrical signs of thickening, but it is less sensitive than imaging.
What does a high left ventricular mass index mean?
The left ventricular mass index estimates the amount of heart muscle relative to your body size. A higher value can indicate thickening, but the result must be compared with reference ranges based on factors such as sex and body size.
Can my ejection fraction be normal if I have hypertensive heart disease?
Yes. Ejection fraction can remain normal early in hypertensive heart disease even when the heart muscle is thickened or relaxation is impaired. Ejection fraction measures how much blood the heart pumps out, while diastolic function describes how the heart fills.
Do high T1 or ECV values on cardiac MRI prove permanent scarring?
No. T1 mapping and ECV estimate diffuse changes in heart tissue, but elevated values do not directly prove permanent microscopic scarring. A cardiologist interprets these findings alongside the rest of the MRI and your clinical history.
How do doctors distinguish hypertensive heart disease from hypertrophic cardiomyopathy or athlete's heart?
Doctors combine your blood pressure history with ECG, echocardiogram, and sometimes cardiac MRI findings. Hypertensive heart disease often causes more even wall thickening, hypertrophic cardiomyopathy may cause disproportionate thickening, and athlete's heart is associated with intense long-term exercise; overlapping patterns may require specialist review.
Why are kidney tests included when evaluating hypertensive heart disease?
High blood pressure can affect the kidneys, and a urine albumin-creatinine ratio checks for protein leaking into the urine. An abnormal result does not by itself prove blood-pressure-related damage because diabetes and primary kidney disease can also cause protein in the urine.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.My report mentions 'concentric hypertrophy'—how does this differ from the thickening seen in other heart conditions?
  2. 2.What is my 'Left Ventricular Mass Index' (LVMI), and how much higher is it than the normal range for my sex?
  3. 3.If my 'ejection fraction' is normal, why does the report still indicate I have 'diastolic dysfunction'?
  4. 4.My MRI shows 'elevated ECV' or 'T1 values'—does this mean I have permanent scarring or just reversible stiffness?
  5. 5.Are there any features on my imaging, like 'asymmetric thickening' or 'mid-wall LGE,' that might suggest I have something other than hypertensive heart disease?
  6. 6.Do my kidney tests, like the urine albumin-creatinine ratio, show any signs that high blood pressure is affecting other organs besides my heart?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Challenges in Echocardiography for the Diagnosis and Prognosis of Non-Ischemic Hypertensive Heart Disease.

    Kadoglou NPE, Mouzarou A, Hadjigeorgiou N, et al.

    Journal of clinical medicine 2024; (13(9)) doi:10.3390/jcm13092708.

    PMID: 38731238
  2. 2

    Selecting the optimal method for assessment of hypertension-mediated organ damage: a personalized approach.

    Gerdts E, Benetos A, Bruno RM, et al.

    European journal of preventive cardiology 2026; (33(7)):1021-1032 doi:10.1093/eurjpc/zwag052.

    PMID: 41603527
  3. 3

    Prognostic implications of left ventricular hypertrophy diagnosed on electrocardiogram vs echocardiography.

    Pedersen LR, Kristensen AMD, Petersen SS, et al.

    Journal of clinical hypertension (Greenwich, Conn.) 2020; (22(9)):1647-1658 doi:10.1111/jch.13991.

    PMID: 32813895
  4. 4

    The association of severity of retinal vascular changes and cardiac remodelling in systemic hypertension.

    Varghese M, Adhyapak SM, Thomas T, et al.

    Therapeutic advances in cardiovascular disease 2016; (10(4)):224-30 doi:10.1177/1753944716630869.

    PMID: 26879197
  5. 5

    Hypertension and left ventricular geometry: Diagnosis, prognosis, and management.

    Mutai SM, Kadambi N, Moazzam M, Oktay AA

    EXCLI journal 2026; (25()):756-775 doi:10.17179/excli2026-9416.

    PMID: 42376431
  6. 6

    Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in hypertension and associated with left ventricular remodeling.

    Wang S, Hu H, Lu M, et al.

    European radiology 2017; (27(11)):4620-4630 doi:10.1007/s00330-017-4841-9.

    PMID: 28439652
  7. 7

    Increased extracellular volume and altered mechanics are associated with LVH in hypertensive heart disease, not hypertension alone.

    Kuruvilla S, Janardhanan R, Antkowiak P, et al.

    JACC. Cardiovascular imaging 2015; (8(2)):172-80.

    PMID: 25577446
  8. 8

    Secondary Hypertension in Children and Adolescents: Novel Insights.

    Chrysaidou K, Chainoglou A, Karava V, et al.

    Current hypertension reviews 2020; (16(1)):37-44 doi:10.2174/1573402115666190416152820.

    PMID: 31038068
  9. 9

    The role of diagnostic modalities in differentiating hypertensive heart disease and hypertrophic cardiomyopathy: strategies in adults for potential application in paediatrics.

    Wagner MJ, Morgan C, Rodriguez Lopez S, et al.

    Cardiology in the young 2025; (35(1)):1-15 doi:10.1017/S1047951124026052.

    PMID: 39849888
  10. 10

    Hypertensive heart disease versus hypertrophic cardiomyopathy: multi-parametric cardiovascular magnetic resonance discriminators when end-diastolic wall thickness ≥ 15 mm.

    Rodrigues JC, Rohan S, Ghosh Dastidar A, et al.

    European radiology 2017; (27(3)):1125-1135 doi:10.1007/s00330-016-4468-2.

    PMID: 27368925
  11. 11

    T1 Mapping in Discrimination of Hypertrophic Phenotypes: Hypertensive Heart Disease and Hypertrophic Cardiomyopathy: Findings From the International T1 Multicenter Cardiovascular Magnetic Resonance Study.

    Hinojar R, Varma N, Child N, et al.

    Circulation. Cardiovascular imaging 2015; (8(12)).

    PMID: 26659373
  12. 12

    Global longitudinal strain differentiates physiological hypertrophy from maladaptive remodeling.

    Bewarder Y, Lauder L, Kulenthiran S, et al.

    International journal of cardiology. Heart & vasculature 2022; (40()):101044 doi:10.1016/j.ijcha.2022.101044.

    PMID: 35573652
  13. 13

    Discrimination of the "Athlete's Heart" from real disease by electrocardiogram and echocardiogram.

    Erickson CC

    Cardiology in the young 2017; (27(S1)):S80-S88 doi:10.1017/S1047951116002286.

    PMID: 28084953
  14. 14

    Cardiovascular implications in adolescent and young adult hypertension.

    Raina R, Khooblall A, Shah R, et al.

    Reviews in cardiovascular medicine 2022; (23(5)):166 doi:10.31083/j.rcm2305166.

    PMID: 39077603
  15. 15

    Severe Left Ventricular Hypertrophy, Small Pericardial Effusion, and Diffuse Late Gadolinium Enhancement by Cardiac Magnetic Resonance Suspecting Cardiac Amyloidosis: Endomyocardial Biopsy Reveals an Unexpected Diagnosis.

    Hofmann NP, Giusca S, Klingel K, et al.

    Case reports in cardiology 2016; (2016()):2461502 doi:10.1155/2016/2461502.

    PMID: 27247807
  16. 16

    Myocardial strain in hypertension: a meta-analysis of two-dimensional speckle tracking echocardiographic studies.

    Tadic M, Sala C, Carugo S, et al.

    Journal of hypertension 2021; (39(10)):2103-2112 doi:10.1097/HJH.0000000000002898.

    PMID: 34054054
  17. 17

    Evaluation of Left Atrial Function in Patients with Hypertensive Heart Disease and Preserved Ejection Fraction Using Real-Time, Three- Dimensional Speckle Tracking Imaging.

    He X, Yang X, Guo P, Ran H

    Kardiologiia 2025; (65(8)):63-70 doi:10.18087/cardio.2025.8.n2856.

    PMID: 40927936
  18. 18

    Left atrial dilatation: A target organ damage in young to middle-age hypertensive patients. The Campania Salute Network.

    Mancusi C, Canciello G, Izzo R, et al.

    International journal of cardiology 2018; (265()):229-233 doi:10.1016/j.ijcard.2018.03.120.

    PMID: 29628278
  19. 19

    Imaging predictors of incident heart failure: a systematic review and meta-analysis.

    Georgiopoulos G, Aimo A, Barison A, et al.

    Journal of cardiovascular medicine (Hagerstown, Md.) 2021; (22(5)):378-387 doi:10.2459/JCM.0000000000001133.

    PMID: 33136816
  20. 20

    Echocardiographic assessment in arterial hypertension: a contemporary narrative review.

    Naderi H, Victor K, Williams L, et al.

    Echo research and practice 2026; (13(1)).

    PMID: 42366420

This page is for informational purposes only and does not constitute medical advice. It explains how clinicians evaluate hypertensive heart disease, but your cardiology team must interpret your ECG, imaging, and kidney results in context.

Get notified when new evidence is published on hypertensive heart disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.